CN112087999A - 用于对映体富集的或纯的安非他酮的剂型和方法 - Google Patents

用于对映体富集的或纯的安非他酮的剂型和方法 Download PDF

Info

Publication number
CN112087999A
CN112087999A CN201980026874.5A CN201980026874A CN112087999A CN 112087999 A CN112087999 A CN 112087999A CN 201980026874 A CN201980026874 A CN 201980026874A CN 112087999 A CN112087999 A CN 112087999A
Authority
CN
China
Prior art keywords
bupropion
dosage form
human
dextromethorphan
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980026874.5A
Other languages
English (en)
Chinese (zh)
Inventor
赫里奥特·塔布提奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Priority to CN202510967625.3A priority Critical patent/CN120827545A/zh
Publication of CN112087999A publication Critical patent/CN112087999A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980026874.5A 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法 Pending CN112087999A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510967625.3A CN120827545A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US62/634,718 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US62/794,469 2019-01-18
US201962809480P 2019-02-22 2019-02-22
US62/809,480 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510967625.3A Division CN120827545A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法

Publications (1)

Publication Number Publication Date
CN112087999A true CN112087999A (zh) 2020-12-15

Family

ID=67688503

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980026874.5A Pending CN112087999A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法
CN202510967625.3A Pending CN120827545A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510967625.3A Pending CN120827545A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法

Country Status (19)

Country Link
EP (1) EP3755312A4 (https=)
JP (3) JP2021513998A (https=)
KR (3) KR20230075531A (https=)
CN (2) CN112087999A (https=)
AU (3) AU2019223187B2 (https=)
BR (1) BR112020017179A2 (https=)
CA (1) CA3092076A1 (https=)
CL (1) CL2020002166A1 (https=)
CR (1) CR20200415A (https=)
EC (1) ECSP20060179A (https=)
IL (2) IL276871B2 (https=)
MA (1) MA51914A (https=)
MX (2) MX2020008704A (https=)
MY (1) MY202993A (https=)
NI (1) NI202000056A (https=)
NZ (1) NZ767378A (https=)
PE (1) PE20211752A1 (https=)
SG (1) SG11202008056SA (https=)
WO (1) WO2019165379A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
KR20220066930A (ko) * 2019-09-20 2022-05-24 액섬 테라퓨틱스, 인크. 에난티오머적으로 풍부한 또는 순수한 부프로피온을 위한 제형 및 방법
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2025259728A1 (en) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CN1819821A (zh) * 2003-08-08 2006-08-16 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20150126541A1 (en) * 2013-11-05 2015-05-07 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20170304230A1 (en) * 2013-11-05 2017-10-26 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501890A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CN1819821A (zh) * 2003-08-08 2006-08-16 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20150126541A1 (en) * 2013-11-05 2015-05-07 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20170304230A1 (en) * 2013-11-05 2017-10-26 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Also Published As

Publication number Publication date
MX2023009281A (es) 2023-08-17
CR20200415A (es) 2021-02-03
NZ767378A (en) 2024-03-22
JP2021513998A (ja) 2021-06-03
WO2019165379A1 (en) 2019-08-29
KR20230075531A (ko) 2023-05-31
KR20240091043A (ko) 2024-06-21
ECSP20060179A (es) 2020-12-31
MA51914A (fr) 2020-12-30
NI202000056A (es) 2021-01-11
IL276871A (en) 2020-10-29
AU2022204521A1 (en) 2022-07-21
EP3755312A1 (en) 2020-12-30
EP3755312A4 (en) 2022-03-16
CA3092076A1 (en) 2019-08-29
AU2019223187B2 (en) 2022-07-28
CL2020002166A1 (es) 2020-10-23
AU2019223187A1 (en) 2020-09-17
BR112020017179A2 (pt) 2020-12-22
JP2024075655A (ja) 2024-06-04
MX2020008704A (es) 2020-12-07
IL276871B2 (en) 2024-11-01
AU2022204521B2 (en) 2024-09-05
MY202993A (en) 2024-05-31
IL313368A (en) 2024-08-01
JP2022153638A (ja) 2022-10-12
PE20211752A1 (es) 2021-09-06
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
CN120827545A (zh) 2025-10-24
KR20210003091A (ko) 2021-01-11
AU2024205858A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US11660273B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US10695304B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20210196704A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
AU2022204521B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20210177834A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20190216801A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20190216800A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11179352B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11331285B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20200222339A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20220249405A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
KR20220066930A (ko) 에난티오머적으로 풍부한 또는 순수한 부프로피온을 위한 제형 및 방법
US20240277635A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40043597A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40043597

Country of ref document: HK